<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02335580</url>
  </required_header>
  <id_info>
    <org_study_id>PVT-LC Prognosis</org_study_id>
    <nct_id>NCT02335580</nct_id>
  </id_info>
  <brief_title>Effect of Portal Vein Thrombosis on the Prognosis of Liver Cirrhosis</brief_title>
  <official_title>Effect of Portal Vein Thrombosis on the Prognosis of Liver Cirrhosis: A Single-center, Prospective, Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Shenyang Military Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of portal vein thrombosis (PVT) in patients with liver cirrhosis is 5-20%.
      Current evidence regarding the effect of portal vein thrombosis on the prognosis of cirrhotic
      patients remains under debate. Considering that PVT potentially elevates the portal pressure
      and thereby increase the risk of variceal bleeding, we focus on the patients with high-risk
      varices and variceal bleeding as the study population. Thus, the main goals are to analyze
      the effect of PVT on the incidence of first variceal bleeding in patients without any prior
      bleeding history but with high-risk varices, the incidence of recurrent variceal bleeding in
      patients with a history of variceal bleeding, and the treatment failure rate of variceal
      bleeding in patients with acute variceal bleeding. Certainly, the survival is also observed
      in all patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6-24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>First bleeding</measure>
    <time_frame>0-24 months</time_frame>
    <description>As for the patients without any prior history of bleeding but with high-risk varices, the first bleeding was observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrent bleeding</measure>
    <time_frame>0-24 months</time_frame>
    <description>As for the patients with a prior history of bleeding, the recurrent bleeding was observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment failure rate of acute variceal bleeding</measure>
    <time_frame>5 days</time_frame>
    <description>As for the patients with acute variceal bleeding, the 5-day treatment failure of acute bleeding was observed.</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Portal Vein</condition>
  <condition>Venous Thrombosis</condition>
  <condition>Varicose Veins</condition>
  <condition>Hemorrhage</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatostatin and its analogs</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic sclerotherapy, endoscopic variceal ligation, endoscopic tissue glue injection</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Study population should be the patients with a diagnosis with liver cirrhosis who were
        admitted to the Department of Gastroenterology of General Hospital of Shenyang Military
        Area.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A diagnosis of liver cirrhosis.

          2. Patients should be diagnosed with high-risk varices endoscopically, or a prior history
             of variceal bleeding, or an episode of acute variceal bleeding.

          3. Patients agreed to undergo endoscopy to evaluate the presence and severity of varices.

          4. Patients agreed to undergo contrast-enhanced CT scans to evaluate the portal vein
             patency. But if an abdominal contrast-enhanced CT scans was performed within 3 months
             after admission, it was not necessarily repeated.

        Exclusion Criteria:

          1. Non-cirrhotic patients.

          2. Malignancy.

          3. Contrast-enhanced CT scans were neither feasible nor available.

          4. Severe cardiopulmonary diseases.

          5. Severe infectious diseases.

          6. Pregnant or breastfeeding.

          7. Allergic to contrast agents.

          8. Poor adherence.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaozhong Guo, M.D.</last_name>
    <phone>86-24-28897603</phone>
    <email>guo_xiao_zhong@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Gastroenterology, General Hospital of Shenyang Military Area</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110840</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingshun Qi, MD</last_name>
      <phone>86-18909881019</phone>
      <email>xingshunqi@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiaozhong Guo, MD</last_name>
      <email>guo_xiao_zhong@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xiaozhong Guo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hongyu Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yue Hou, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xu Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaolin Sun, MB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yongguo Zhang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Di Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chunyan Wu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xingshun Qi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Qi X, Han G, Fan D. Management of portal vein thrombosis in liver cirrhosis. Nat Rev Gastroenterol Hepatol. 2014 Jul;11(7):435-46. doi: 10.1038/nrgastro.2014.36. Epub 2014 Apr 1. Review.</citation>
    <PMID>24686266</PMID>
  </reference>
  <reference>
    <citation>Qi X, Yang Z, Fan D. Spontaneous resolution of portal vein thrombosis in cirrhosis: where do we stand, and where will we go? Saudi J Gastroenterol. 2014 Sep-Oct;20(5):265-6. doi: 10.4103/1319-3767.141680.</citation>
    <PMID>25253359</PMID>
  </reference>
  <reference>
    <citation>Qi X, Wang J, Chen H, Han G, Fan D. Nonmalignant partial portal vein thrombosis in liver cirrhosis: to treat or not to treat? Radiology. 2013 Mar;266(3):994-5. doi: 10.1148/radiol.12122259.</citation>
    <PMID>23431230</PMID>
  </reference>
  <reference>
    <citation>Qi X, Han G, He C, Yin Z, Guo W, Niu J, Fan D. CT features of non-malignant portal vein thrombosis: a pictorial review. Clin Res Hepatol Gastroenterol. 2012 Dec;36(6):561-8. doi: 10.1016/j.clinre.2012.05.021. Epub 2012 Aug 9.</citation>
    <PMID>22883835</PMID>
  </reference>
  <reference>
    <citation>Qi X, Bai M, Yang Z, Yuan S, Zhang C, Han G, Fan D. Occlusive portal vein thrombosis as a new marker of decompensated cirrhosis. Med Hypotheses. 2011 Apr;76(4):522-6. doi: 10.1016/j.mehy.2010.12.007. Epub 2011 Jan 8.</citation>
    <PMID>21216538</PMID>
  </reference>
  <reference>
    <citation>Qi X, Han G, Wang J, Wu K, Fan D. Degree of portal vein thrombosis. Hepatology. 2010 Mar;51(3):1089-90. doi: 10.1002/hep.23397.</citation>
    <PMID>19957371</PMID>
  </reference>
  <reference>
    <citation>Qi X, Han G, Bai M, Fan D. Stage of portal vein thrombosis. J Hepatol. 2011 May;54(5):1080-2; author reply 1082-3. doi: 10.1016/j.jhep.2010.10.034. Epub 2010 Dec 5.</citation>
    <PMID>21145872</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2015</study_first_submitted>
  <study_first_submitted_qc>January 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2015</study_first_posted>
  <last_update_submitted>August 8, 2016</last_update_submitted>
  <last_update_submitted_qc>August 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Xingshun Qi</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Varicose Veins</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

